| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 1.434 | 943 | 22.621 | 5.212 | 10.067 | 8.404 | 5.452 | 1.319 |
| Total Income - EUR | - | - | 30.849 | 1.623 | 23.026 | 7.922 | 11.326 | 9.415 | 5.705 | 2.359 |
| Total Expenses - EUR | - | - | 22.499 | 2.574 | 3.136 | 5.161 | 9.620 | 16.415 | 3.368 | 3.161 |
| Gross Profit/Loss - EUR | - | - | 8.350 | -951 | 19.890 | 2.761 | 1.706 | -7.000 | 2.337 | -802 |
| Net Profit/Loss - EUR | - | - | 8.327 | -964 | 19.525 | 2.689 | 1.542 | -7.252 | 1.963 | -802 |
| Employees | - | - | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
Check the financial reports for the company - Novartis Andrecos Fruct Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 3.255 | 2.782 | 2.323 | 1.881 | 3.802 | 2.332 | 1.151 | 547 |
| Current Assets | - | - | 9.065 | 7.751 | 27.252 | 33.892 | 37.470 | 33.680 | 32.170 | 30.798 |
| Inventories | - | - | 1.131 | 0 | 0 | 7.967 | 16.141 | 20.033 | 18.595 | 18.491 |
| Receivables | - | - | 8 | 0 | 0 | 44 | 0 | 2.005 | 6.017 | 5.837 |
| Cash | - | - | 7.926 | 7.751 | 27.252 | 25.882 | 21.329 | 11.642 | 7.557 | 6.470 |
| Shareholders Funds | - | - | 8.370 | 7.253 | 26.637 | 28.822 | 29.675 | 22.212 | 24.107 | 23.171 |
| Social Capital | - | - | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | 898 | 697 | 809 | 5.262 | 10.333 | 13.257 | 9.213 | 8.174 |
| Income in Advance | - | - | 3.052 | 2.583 | 2.128 | 1.690 | 1.263 | 543 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "113 - 113" | |||||||||
| CAEN Financial Year |
113
|
|||||||||
Comments - Novartis Andrecos Fruct Srl